Back to search

Poland· PL-100461753

Rivaroxaban Medreg

A rivaroxaban product containing rivaroxabanum, registered in Poland by Medreg s.r.o.. The same ATC class is registered in 15 of our 19 countries.

ATC B01AF01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRivaroxaban MedregATCB01AF01REGISTER NO.PL-100461753PACKS LISTED7CHECKEDSeptember 27, 2026

Where it is registered

Rivaroxaban is registered in 15 of 19 countries.

Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Rivaroxaban · ATC B01AF01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivaroxaban costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Rivaroxaban · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • US United States$5.20 (acquisition cost)
  • CH Switzerland$2.66
  • IT Italy$1.08
  • FR France$0.67
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Rivaroxabanum
Manufacturer
Medreg s.r.o.
Country
Poland (PL)
ATC code
B01AF01
ATC class
Rivaroxaban
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 7

  • gtin
    08595566456467
  • gtin
    08595566456412
  • gtin
    08595566456443
  • gtin
    08595566456450
  • gtin
    08595566456436
  • gtin
    08595566456474
  • gtin
    08595566456429

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for rivaroxaban.

Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rivaroxaban · interactions on record

391 records

  • 134 severe
  • 213 moderate
  • 2 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe

42 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rivaroxaban in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rivaroxaban products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Rivahib, Rivaroksaban Grindeks
  • Belgium · Rivaroxaban, Rivaroxaban  Eg
  • Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
  • Cyprus · Enkia, Naxat
  • Czechia · Axaltra, Bevimlar
  • Germany · Elmardya, Rivadia
  • Denmark · Blomensy, Dovequa
  • Estonia · Enkia, Kardatuxan
  • Spain · Blomensy, Elmardya
  • Finland · Blomensy, Dovequa
  • France · Elmardya, Rivaroxaban Almus
  • United Kingdom (Northern Ireland) · Rivaroxaban, Rivaroxaban Abdi
  • Greece · Blomensy, Cinstel
  • Croatia · Aban, Bevimlar
  • Hungary · Dovequa, Evoxyr
  • Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
  • Iceland · Agublon, Barsovi
  • Italy · Ellebax, Indifaxa
  • Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
  • Lithuania · Enkia, Kardatuxan
  • Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
  • Latvia · Kardatuxan, Mibrex
  • Malta · Enkia, Naxat
  • Netherlands · Blomensy, Rivaroksaban Grindeks
  • Norway · Dovequa, Rivaroxaban Accord
  • Portugal · Closderive, Enkia
  • Romania · Closderive, Enkia
  • Sweden · Bevimlar, Blomensy
  • Slovenia · Dovequa, Ribas
  • Slovakia · Assubex, Bevimlar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bc9770c5-b9fc-4b32-af7f-ab17087112cd
GET /v1/drugs/bc9770c5-b9fc-4b32-af7f-ab17087112cd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "10 mg",
  "packaging": "08595566456467 ¦ Rp ¦ 151134\n98 tabl.\n08595566456412 ¦ Rp ¦ 151135\n5 tabl.\n08595566456443 ¦ Rp ¦ 151136\n28 tabl.\n08595566456450 ¦ Rp ¦ 151137\n30 tabl.\n08595566456436 ¦ Rp ¦ 151138\n14 tabl.\n08595566456474 ¦ Rp ¦ 151139\n100 tabl.\n08595566456429 ¦ Rp ¦ 151140\n10 tabl.",
  "substance": "Rivaroxabanum 10 mg",
  "common_name": "Rivaroxabanum",
  "pl_product_id": "100461753",
  "pozwolenie_nr": "28016",
  "auth_procedure": "DCP",
  "authorisation_validity": "2028-09-22"
}

See everything about rivaroxaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.